Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 11, 2011 - Issue 4
Submit an article Journal homepage
305
Views
8
CrossRef citations to date
0
Altmetric
Theme: ADHD - Special Report

Transitioning to OROS® methylphenidate from atomoxetine is effective in children and adolescents with ADHD

Käthe Niederkirchner Private Practice, Child and Adolescent Medicine, Berlin, Germany; Private Practice, Child and Adolescent Medicine, Berlin, Germany
,
Lara Slawik Janssen-Cilag GmbH, Raiffeisenstrasse 8, D-41470 Neuss, Germany; Janssen-Cilag GmbH, Raiffeisenstrasse 8, D-41470 Neuss, Germany
,
Detlef Wermelskirchen Janssen-Cilag GmbH, Raiffeisenstrasse 8, D-41470 Neuss, Germany; Janssen-Cilag GmbH, Raiffeisenstrasse 8, D-41470 Neuss, Germany
,
Klaus Rettig GEM Gesellschaft für Evaluation und Qualitätssicherung in der Medizin mbH, Meerbuscher Str. 47, D-40670 Meerbusch, Germany; GEM Gesellschaft für Evaluation und Qualitätssicherung in der Medizin mbH, Meerbuscher Str. 47, D-40670 Meerbusch, Germany
&
Barbara Schäuble Janssen EMEA, Medical Affairs, Johnson & Johnson Platz 5a, D-41470 Neuss, Germany; Janssen EMEA, Medical Affairs, Johnson & Johnson Platz 5a, D-41470 Neuss, Germany
Pages 499-508 | Published online: 09 Jan 2014

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Carlos Carona, Neuza Silva & Helena Moreira. (2015) Applying a developmental approach to quality of life assessment in children and adolescents with psychological disorders: challenges and guidelines. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 47-70.
Read now
Kavita Gajria, Mei Lu, Vanja Sikirica, Peter Greven, Yichen Zhong, Paige Qin & Jipan Xie. (2014) Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review. Neuropsychiatric Disease and Treatment 10, pages 1543-1569.
Read now
Christian Wolff, Adam Alfred, Anton Lindermüller, Klaus Rettig, Fritz Mattejat, Martin Gerwe, Lara Slawik & Barbara Schäuble. (2011) Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study. Current Medical Research and Opinion 27:sup2, pages 35-44.
Read now

Articles from other publishers (5)

Joyce Costa Melgaço Faria, Lívia Juliana Reis Duarte, Lilian de Abreu Ferreira, Vívian Thaise da Silveira, Cristiane Menezes de Pádua & Edson Perini. (2021) “Real‐world” effectiveness of methylphenidate in improving the academic achievement of Attention‐Deficit Hyperactivity Disorder diagnosed students—A systematic review. Journal of Clinical Pharmacy and Therapeutics 47:1, pages 6-23.
Crossref
Ole Jakob Storebø, Nadia Pedersen, Erica Ramstad, Maja Laerke Kielsholm, Signe Sofie Nielsen, Helle B Krogh, Carlos R Moreira-Maia, Frederik L Magnusson, Mathilde Holmskov, Trine Gerner, Maria Skoog, Susanne Rosendal, Camilla Groth, Donna Gillies, Kirsten Buch Rasmussen, Dorothy Gauci, Morris Zwi, Richard Kirubakaran, Sasja J Håkonsen, Lise Aagaard, Erik Simonsen & Christian Gluud. (2018) Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database of Systematic Reviews.
Crossref
Nicola C. Savill, Jan K. Buitelaar, Ernie Anand, Kathleen Ann Day, Tamás Treuer, Himanshu P. Upadhyaya & David Coghill. (2015) The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research. CNS Drugs 29:2, pages 131-151.
Crossref
Martin A. Katzman & Tia Sternat. (2014) A Review of OROS Methylphenidate (Concerta®) in the Treatment of Attention-Deficit/Hyperactivity Disorder. CNS Drugs 28:11, pages 1005-1033.
Crossref
Michael Berek, Andreas Kordon, Ludger Hargarter, Fritz Mattejat, Lara Slawik, Klaus Rettig & Barbara Schäuble. (2011) Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?. Child and Adolescent Psychiatry and Mental Health 5:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.